Deep Track Capital LP Sells 100,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX)

Deep Track Capital LP lowered its stake in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) by 10.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 867,000 shares of the company's stock after selling 100,000 shares during the period. Deep Track Capital LP owned 8.34% of Avalo Therapeutics worth $6,442,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of AVTX. Affinity Asset Advisors LLC boosted its position in Avalo Therapeutics by 1,123.9% during the fourth quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company's stock worth $4,092,000 after purchasing an additional 505,765 shares during the period. Geode Capital Management LLC increased its holdings in Avalo Therapeutics by 937.0% during the 4th quarter. Geode Capital Management LLC now owns 104,853 shares of the company's stock worth $779,000 after acquiring an additional 94,742 shares during the period. Allostery Investments LP purchased a new position in Avalo Therapeutics during the fourth quarter worth about $545,000. BVF Inc. IL increased its position in shares of Avalo Therapeutics by 7.2% in the fourth quarter. BVF Inc. IL now owns 1,036,679 shares of the company's stock worth $7,703,000 after purchasing an additional 69,679 shares during the last quarter. Finally, Bank of Montreal Can purchased a new stake in shares of Avalo Therapeutics during the 4th quarter valued at $446,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AVTX has been the topic of several research reports. HC Wainwright reissued a "neutral" rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Piper Sandler began coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They issued an "overweight" rating and a $48.00 target price on the stock. Wedbush reaffirmed an "outperform" rating and set a $18.00 price target on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Jefferies Financial Group started coverage on shares of Avalo Therapeutics in a report on Tuesday, March 25th. They issued a "buy" rating and a $23.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Avalo Therapeutics in a research note on Tuesday, March 25th. They set a "buy" rating and a $36.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $33.00.

Avalo Therapeutics Trading Down 5.6 %

Shares of NASDAQ:AVTX opened at $4.74 on Wednesday. Avalo Therapeutics, Inc. has a 12-month low of $4.15 and a 12-month high of $16.00. The stock has a fifty day simple moving average of $6.30 and a two-hundred day simple moving average of $8.29.

Avalo Therapeutics Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

Want to see what other hedge funds are holding AVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.